Study of Tocilizumab and Atezolizumab to Treat Adults with Advanced or Recurrent Non-Small Cell Lung Cancer Not Responding to First-Line Immune Therapy

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining tocilizumab with atezolizumab to treat adults with locally advanced or metastatic non-small cell lung cancer NSCLC that did not respond to first-line immune checkpoint inhibitor therapy. This study includes participants with advanced non-squamous NSCLC who have received at least one prior therapy including a checkpoint inhibitor. The trial is a phase Ib-II interventional study sponsored by Abramson Cancer Center at Penn Medicine. Participants receive infusions of atezolizumab at a dose of 1200 mg and tocilizumab at either 6 mgkg or 4 mgkg every 21 days. The study monitors the effects of this combination therapy over time, with treatments repeated every three weeks. This trial does not include placebo groups and is not blinded. During the study, participants undergo radiologic disease assessments at 12 weeks to measure the overall response rate. Researchers also track overall survival, progression-free survival, and dose-limiting toxicities up to 24 months after treatment begins. Safety is monitored closely, including any toxicities related to prior immunotherapy. Participants are followed until death, last contact, or study closure, with ongoing assessments to evaluate disease progression and treatment response.

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy